Business & Tech
Luxembourg Company Purchasing Framingham Biotech Firm for $140 Million
The Framingham-based company had projected $95 million in revenues.
Eurofins Scientific of Luxemboroug announced it is purchasing Framingham-based Boston Heart Diagnostics for $140 million.
The deal was announced earlier this month. The deal is expected to be finalized in early February 2015.
Boston Heart, a Framingham-based biotech firm, projected 2014 revenues of $95 million.
Find out what's happening in Framinghamfor free with the latest updates from Patch.
“Boston Heart will continue to provide our breakthrough testing and services to clinicians and patients under the Boston Heart name and in the same manner our customers have come to expect,” CEO Susan Hertzberg, said in a press release.
The Bain Capital Ventures portfolio company has 350 employees, who work to identify and reduce the risk of cardiovascular disease, diabetes, and other chronic conditions. .
Find out what's happening in Framinghamfor free with the latest updates from Patch.
No layoffs, site consolidations, or restructuring is expected with the sale.
The company is located at 175 Crossing Boulevard in Framingham.
Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.
